CN106267166A - A kind of dental pulp regeneration paste and preparation method thereof - Google Patents
A kind of dental pulp regeneration paste and preparation method thereof Download PDFInfo
- Publication number
- CN106267166A CN106267166A CN201610861935.8A CN201610861935A CN106267166A CN 106267166 A CN106267166 A CN 106267166A CN 201610861935 A CN201610861935 A CN 201610861935A CN 106267166 A CN106267166 A CN 106267166A
- Authority
- CN
- China
- Prior art keywords
- paste
- dental pulp
- weight portion
- estradiol
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003074 dental pulp Anatomy 0.000 title claims abstract description 44
- 238000011069 regeneration method Methods 0.000 title claims abstract description 38
- 230000008929 regeneration Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000009306 yunnan baiyao Substances 0.000 claims abstract description 25
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 21
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 21
- 102000013275 Somatomedins Human genes 0.000 claims abstract description 21
- 229960005309 estradiol Drugs 0.000 claims abstract description 21
- 229930182833 estradiol Natural products 0.000 claims abstract description 21
- 229960003405 ciprofloxacin Drugs 0.000 claims abstract description 19
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960000282 metronidazole Drugs 0.000 claims abstract description 19
- 229920001661 Chitosan Polymers 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 11
- 239000000758 substrate Substances 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 210000000214 mouth Anatomy 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000003981 vehicle Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 5
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 5
- -1 polysiloxane Polymers 0.000 claims description 5
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 210000004262 dental pulp cavity Anatomy 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000001771 impaired effect Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 201000004328 Pulpitis Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 206010037464 Pulpitis dental Diseases 0.000 description 4
- 210000004268 dentin Anatomy 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000002308 calcification Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 208000004480 periapical periodontitis Diseases 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005258 dental pulp stem cell Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000004746 tooth root Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003103 anti-anaerobic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001883 nitrergic effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000021749 root development Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Physiology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of dental pulp regeneration paste, described dental pulp regeneration paste includes active component, described active component is made up of YUNNAN BAIYAO, metronidazole, ciprofloxacin, type-1 insulin like growth factor, estradiol and chitosan, each component content in active component is as follows: YUNNAN BAIYAO 10 ~ 40 weight portion, metronidazole 10 ~ 40 weight portion, ciprofloxacin 10 ~ 40 weight portion, type-1 insulin like growth factor 0.01 ~ 1 weight portion, estradiol 0.01 ~ 1 weight portion, chitosan 5 ~ 20 weight portion.The present invention has the following technical effect that 1, the present invention in clinical use, relative to traditional root canal therapy, clinical oral doctor is easy and simple to handle, and treatment time is short, and patient's further consultation number of times is few, drastically increases the therapeutic efficiency of disease of pulp of tooth.Because of without carrying out root pipe mechanical preparation, it is to avoid root canal wall tissue secondary is impaired, reduces the risk of odontagma.
Description
Technical field
The invention belongs to retain when dental treatment technical field of pharmaceuticals, especially one treat the diseases such as pulpitis and live
Marrow, the paste of promotion tissue regeneration, be placed in this paste in pulp tissue, can activate stem cells hyperplasia in pulp tissue, differentiation
Potential, improve the antiinflammatory of pulp tissue, tissue repair and regeneration capacity, eliminate local pulp tissue inflammation, recover dental pulp, tooth
The normal physiological function of soma.
Background technology
Pulpitis, the disease such as periapical periodontitis is the frequently-occurring disease that modern is common, and bacterial penetration to Its pulp makes softness
Pulp cells infects death.Clinical oral routine is all to use root canal therapy (being commonly called as killing dental nerve) carry out debridement and disappear at present
Except infecting, root canal therapy has played great function in preserving tissue of tooth, but its drawback the most increasingly allows people be difficult to suddenly
Depending on, mainly show as the tooth after root canal owing to being in without marrow state, lose the nutrition of dental pulp, feel, defend and formed
Function, intensity substantially reduces, and easily becomes fragile, and is susceptible to jackknifing；Root canal system is intricate, and patient is often difficult to feel in root pipe
Dye thing is cleaned out, and remaining bacteria easily causes residual pulpitis, adds the uncertainty of root canal late result, and indication is subject to
Limit, although many suffers from tooth extends retention time, but the most healthy tooth is susceptible to defect, thus causes loss of tooth.Cause
This preserves vital pulp, finds more preferable, more reliable treatment means imperative.It is true that since nineteen thirties,
Oral cavity workers begin to explore the modes such as the preservation measure of vital pulp, main employing calcium hydroxide lid marrow, it is thus achieved that higher
Success rate, but still suffer from needing repeatedly going to a doctor, technique sensitive height, poor operability, damage remaining dental pulp, without induced tissue again
The shortcomings such as raw function.To this end, we develop a kind of dental pulp regeneration paste, on the basis of promoting inflammatory resolution, at utmost
Ground excavates dental pulp stem cell potential, promotes reparation and the regeneration of remaining pulp tissue.
Summary of the invention
It is an object of the invention to tooth to be made owing to being in without marrow state for root canal, lose the nutrition of dental pulp, sense
Feeling, defend and formed function, intensity substantially reduces, and easily becomes fragile, and is susceptible to jackknifing, thus causes loss of tooth etc. a series of
Problem, invents a kind of vital pulp that can preserve and can effect a radical cure again the dental pulp regeneration paste of the diseases such as pulpitis, provide its preparation side simultaneously
Method.
The dental pulp regeneration paste of the present invention, including active component, described active component is by YUNNAN BAIYAO, metronidazole, ring
Third husky star, type-1 insulin like growth factor, estradiol and chitosan composition, each component content in active component is as follows: Yunnan
BAIYAO 10 ~ 40 weight portion, metronidazole 10 ~ 40 weight portion, ciprofloxacin 10 ~ 40 weight portion, type-1 insulin like growth factor
(IGF-1) 0.01 ~ 1 weight portion, estradiol 0.01 ~ 1 weight portion, chitosan 5 ~ 20 weight portion.
Described dental pulp regeneration paste also include oral cavity paste substrate, described oral cavity paste substrate be olive oil or
Polysiloxane oil；The w/v of described active component and oral cavity paste substrate is 1 gram: 1 ~ 1.5mL.
Or described dental pulp regeneration paste also includes oral cavity paste substrate, every 33g active component is added with including becoming as follows
The oral cavity paste substrate divided:
Composition A: mass concentration is the citric acid 1mL of 19%, ethyl hydroxybenzoate 0.015 gram, distilled water 100mL；
Composition B: glycerol 10mL.
The preparation method of the dental pulp regeneration paste of the present invention, comprises the following steps:
1) by YUNNAN BAIYAO, metronidazole, ciprofloxacin, type-1 insulin like growth factor, estradiol and chitosan by certain weight
Proportioning, grinds to form impalpable powder, crosses 100 mesh sieves；
2) with oral cavity paste substrate, the above-mentioned powder preparing gained is mixed tune to mix to butyrous, obtain the paste stirred
Preparation.
The preparation method of the dental pulp regeneration paste of the present invention, comprises the steps:
1) by YUNNAN BAIYAO, metronidazole, ciprofloxacin, type-1 insulin like growth factor, estradiol by the weight proportion set, grind
Wear into fine powder, cross 100 mesh sieves, obtain powder；
2) citric acid is dissolved in mix homogeneously in distilled water, then adds ethyl hydroxybenzoate mixing, in stirring, add chitosan make into
Gel-type vehicle；
3) first by ground YUNNAN BAIYAO, metronidazole, ciprofloxacin, type-1 insulin like growth factor, estradiol powder and glycerol
Stir, the most slowly add in gel-type vehicle, stir evenly and i.e. obtain dental pulp regeneration paste.
The using method of the dental pulp regeneration paste of the present invention: directly paste is injected in root pipe.
The mechanism of action of the present invention is as follows:
Paste of the present invention is with antibiotic such as YUNNAN BAIYAO, metronidazole, ciprofloxacins as primary raw material, in conjunction with other active factorses
(type-1 insulin like growth factor, estradiol), mixs homogeneously by a certain percentage with paste substrate, chitosan stent material during making.
Metronidazole in this product is typical anti-anaerobic agent, owing to the antibacterial in most Pulpal pathosis is from deep cavity, deep dental caries
Hole is considered to be anaerobic environment, beneficially the growth and breeding of anaerobe, and the nitrergic in metronidazole makes low redox potential
Anaerobe reduction, produce complex virulent to antibacterial itself, thus suppress the synthesis of bacteria dna, boil on the nape opposite the mouth
The anaerobe caused a disease in chamber has specially good effect.Ciprofloxacin is the fluoroquinolones of synthetic, has broad-spectrum antibacterial action, especially
Aerobic gram negative bacilli and multi-drug resistant bacteria are had higher antibacterial activity, fibroblastic life can also be promoted simultaneously
Become, contribute to the reparation of inflammatory tissue.YUNNAN BAIYAO in this product is China's Chinese medicine, uses with a long history, has many
Plant active component, have hemostatic analgesia, antiinflammatory heat radiation, blood circulation promoting and blood stasis dispelling, effect of erosion prevention and muscle growing, it is possible to strengthen platelet membrane penetrating
Property, promote platelet component adenylic acid and the release of calcium；Improve the microcirculation obstacle that macromolecule right rotary glycoside causes；Suppression
Inflammatory mediator histamine and the release of prostaglandin E.Additionally, the calcium ion in YUNNAN BAIYAO has the work increasing capillary permeability
With, strengthen mass exchange.Therefore, YUNNAN BAIYAO not only can antibacterial, antiinflammatory, ease the pain, and pulp tissue can be promoted
Repair, promote dental pulp blood fortune, and discharge calcium ion entrance dentinal matrix, reparative dentin after calcification, can be formed.Insulin
Like growth factor 1, estradiol have the ability promoting dental pulp stem cell propagation, breaking up, and can form reparative dentin further and protect
Protect pulp tissue from environmental stimuli.Chitosan is a kind of growth activity timbering material, is continue protein, fat, carbon hydrate
The indispensable another vital principle of human body after thing, vitamin, mineral, is widely used in food, medicine, has good
Biocompatibility, it is possible to promote osteoblast differentiation and promote calcification, guide tissue regeneration promote Renovate dentin formation,
Being hydrolyzed into oligosaccharide under the effect of lysozyme, chitinase in vivo, its end-product glycosamine equally can be by internal utilization.
The root canal therapy of the most alternative complexity of use of the present invention, preserves and suffers from tooth pulp vitality, recovers
The vitality of tooth, is the direction of following stomatology development.Have been for the present invention and carry out bacteriostatic test, clinical pharmacology, peace
Full property toxicology, cytotoxicity experiment research, the most qualified, can life-time service.
The present invention has the following technical effect that
1, the present invention is in clinical use, and relative to traditional root canal therapy, clinical oral doctor is easy and simple to handle, treatment time
Short, patient's further consultation number of times is few, drastically increases the therapeutic efficiency of disease of pulp of tooth.Because of without carrying out root pipe mechanical preparation, it is to avoid
Root canal wall tissue secondary is impaired, reduces the risk of odontagma.
2, the present invention has preferable antibacterial and anti-inflammation functions, and efficacy stability is lasting, and permeability is strong, and has good biology
The compatibility, without inhibitive ability of immunity, can promote recovery and the dental pulp regeneration of dental pulp normal physiological function, thus significantly improve and suffer from tooth work
The storage rate of marrow.
3, the present invention using China's Chinese medicine YUNNAN BAIYAO as one of formula, Chinese and western medical combine serve good
Effect.YUNNAN BAIYAO not only can antibacterial, antiinflammatory, ease the pain, and the reparation of beneficially pulp tissue, may advantageously facilitate dental pulp
Blood is transported, and discharges calcium ion entrance dentinal matrix, can form reparative dentin after calcification.
4, medicine used by paste formula of the present invention is with low cost, easy to use, safely and effectively, it is simple to clinical large-scale promotion
Use, can greatly save China's effective oral medical resource.
Prescription of the present invention is reasonable, safe and reliable, and medicine source is sufficient, easy to operate, and antibiotic property is strong, can effectively treat dental pulp
Inflammation, the inflammation such as periapical periodontitis, indication is extensive, it is possible to effectively preserves and suffers from tooth pulp vitality, promotes repairing of pulp tissue
Answering and regeneration, have great novelty, representative is the new direction that future, stomatology developed.
Accompanying drawing explanation
Fig. 1 is preoperative X-ray film: infections of dental pulp, and root of the tooth is not grown completely, and the tip of a root is not closed.
Fig. 2 is surgical radiograph: place dental pulp regeneration paste antiinflammatory.
Fig. 3 is postoperative X line sheet: root of the tooth completes to grow, and the tip of a root closes.
Detailed description of the invention
Embodiment 1
The dental pulp regeneration paste of the present embodiment, including paste substrate and active component, active component is as follows: YUNNAN BAIYAO 10g, first
Nitre azoles 10g, ciprofloxacin 10g, type-1 insulin like growth factor 0.01g, estradiol 0.01g and chitosan 5g, paste substrate is
35mL olive oil.
The dental pulp regeneration paste of the present embodiment, uses following methods to be prepared from:
1) by YUNNAN BAIYAO, metronidazole, ciprofloxacin, type-1 insulin like growth factor, estradiol and chitosan by certain weight
Proportioning, grinds to form impalpable powder, crosses 100 mesh sieves；
2) with oral cavity paste substrate, the above-mentioned powder preparing gained is mixed tune to mix to butyrous, obtain the paste stirred
Preparation；
3) the paste-like preparation sterilizing subpackage that will obtain；
4) sterilizing paste good for subpackage is placed at dry sombre lucifuge stores for future use.
Embodiment 2
The dental pulp regeneration paste of the present embodiment, including paste substrate and active component, active component is as follows: YUNNAN BAIYAO 25g, first
Nitre azoles 25g, ciprofloxacin 25g, type-1 insulin like growth factor 0.5g, estradiol 0.5g and chitosan 14g, paste substrate is
135mL olive oil.
Preparation method is with embodiment 1.
Embodiment 3
The dental pulp regeneration paste of the present embodiment, including paste substrate and active component, active component is as follows: YUNNAN BAIYAO 40g, first
Nitre azoles 40g, ciprofloxacin 40g, type-1 insulin like growth factor 1g, estradiol 1g and chitosan 20g, paste substrate is 170mL
Methyl-silicone oil.
Preparation method is with embodiment 1.
Embodiment 4
The dental pulp regeneration paste of the present embodiment, including paste substrate and active component.
Active component is as follows: YUNNAN BAIYAO 10g, metronidazole 10g, ciprofloxacin 10g, type-1 insulin like growth factor
0.01g, estradiol 0.01g and chitosan 5g.
Paste matrix components is as follows: composition A, and mass concentration is the citric acid 1mL of 19%, ethyl hydroxybenzoate 0.015 gram,
Distilled water 100mL；Composition B, glycerol 10mL.
The dental pulp regeneration paste of the present embodiment, uses following methods to be prepared from:
1) by YUNNAN BAIYAO, metronidazole, ciprofloxacin, type-1 insulin like growth factor and estradiol, grind to form fine powder, cross 100 mesh
Sieve, obtains powder；
2) the citric acid 1mL that mass concentration is 19% is dissolved in mix homogeneously in 100mL distilled water, then adds 0.015 gram of nipalgin
Ethyl ester mixes, and adds 3g pharmaceutical grade chitosan and make into gel-type vehicle in stirring；
3) first by ground YUNNAN BAIYAO, metronidazole, ciprofloxacin, type-1 insulin like growth factor and estradiol powder with
10mL glycerol stirs, and the most slowly adds in gel-type vehicle, stirs evenly and i.e. obtains dental pulp regeneration paste；
4) the paste-like preparation sterilizing subpackage that will obtain；
5) sterilizing paste good for subpackage is placed at dry sombre lucifuge stores for future use.
Embodiment 5
Fig. 1-3 is that the paste treatment one example tip of a root immature permanent teeth periapical periodontitis utilizing the embodiment of the present invention 1 is accompanied
The therapeutic process schematic diagram of cheek side fistula.
Fig. 1 is preoperative X-ray film: infections of dental pulp, and root of the tooth is not grown completely, and the tip of a root is not closed.
Fig. 2 is surgical radiograph: place dental pulp regeneration paste antiinflammatory.
Fig. 3 is postoperative X line sheet: root of the tooth completes to grow, and the tip of a root closes.
Concrete treatment operating procedure is as follows:
1, tooth routine local anaesthesia, upper rubber dam are suffered from, art district of sterilizing；
2, suffer from tooth routine removing the necrotic tissue for hole, open marrow and take off top, remove dead pulp, set up root pipe path；
3, conventional tooth sheet of clapping, estimation root pipe general operation length；
4, substantial amounts of medicine cleaning down root pipe is used, envelope dental pulp regeneration paste surrounding in root pipe；
5, further consultation after January, symptom takes a turn for the better.Opening root pipe, ooze out without purulence, drug irrigation root pipe, sharp instrument tool stimulates the tip of a root to go out
Blood, after forming blood clot at blood from overflowing to root canal orifice, covers dental pulp regeneration paste on blood clot, and glass ion is rebasing,
Resin fill；
6, postoperative half a year, check carried out x-ray (Fig. 3) and clinical assessment, it is seen that paste major part absorbs, dental pulp electricity vitality restoration (with
Control teeth), root development is nearly completed, and tooth is without variable color.
The therapeutic effect of embodiment 2-4 is the most similar to Example 1.
Through 3 years 200 example Clinical practice, effect was all similar to Fig. 3.Thus prove that the regeneration paste of the present invention has reason
The therapeutic effect thought, and without any example side effect, clinic is promoted.
The foregoing is only the case study on implementation of the present invention, and be not so limited the scope of the claims of the present invention, every utilization this
Equivalent structure or equivalence flow process that description of the invention and accompanying drawing content are made convert, or are directly or indirectly used in what other were correlated with
Technical field, is the most in like manner included in the scope of patent protection of the present invention.
Part that the present invention does not relate to is the most same as the prior art maybe can use prior art to be realized.
Claims (5)
1. a dental pulp regeneration paste, it is characterised in that described dental pulp regeneration paste includes active component, described activity one-tenth
Dividing and be made up of YUNNAN BAIYAO, metronidazole, ciprofloxacin, type-1 insulin like growth factor, estradiol and chitosan, each component is being lived
Content in property composition is as follows: YUNNAN BAIYAO 10 ~ 40 weight portion, metronidazole 10 ~ 40 weight portion, ciprofloxacin 10 ~ 40 weight
Part, type-1 insulin like growth factor 0.01 ~ 1 weight portion, estradiol 0.01 ~ 1 weight portion, chitosan 5 ~ 20 weight portion.
Dental pulp the most according to claim 1 regeneration paste, it is characterised in that described dental pulp regeneration paste also includes oral cavity
Using paste substrate, described oral cavity paste substrate is olive oil or polysiloxane oil；Described active component and oral cavity are stuck with paste
The w/v of agent substrate is 1 gram: 1 ~ 1.5mL.
Dental pulp the most according to claim 1 regeneration paste, it is characterised in that described dental pulp regeneration paste also includes oral cavity
Using paste substrate, every 33g active component is added with the oral cavity paste substrate including following composition:
Composition A: mass concentration is the citric acid 1mL of 19%, ethyl hydroxybenzoate 0.015 gram, distilled water 100mL；
Composition B: glycerol 10mL.
4. the preparation method of dental pulp regeneration paste as claimed in claim 2, it is characterised in that comprise the following steps:
1) by YUNNAN BAIYAO, metronidazole, ciprofloxacin, type-1 insulin like growth factor, estradiol and chitosan by certain weight
Proportioning, grinds to form impalpable powder, crosses 100 mesh sieves；
2) with oral cavity paste substrate, the above-mentioned powder preparing gained is mixed tune to mix to butyrous, obtain the paste stirred
Preparation.
5. the preparation method of dental pulp regeneration paste as claimed in claim 3, it is characterised in that comprise the steps:
1) by YUNNAN BAIYAO, metronidazole, ciprofloxacin, type-1 insulin like growth factor, estradiol by the weight proportion set, grind
Wear into fine powder, cross 100 mesh sieves, obtain powder；
2) citric acid is dissolved in mix homogeneously in distilled water, then adds ethyl hydroxybenzoate mixing, in stirring, add chitosan make into
Gel-type vehicle；
3) first by ground YUNNAN BAIYAO, metronidazole, ciprofloxacin, type-1 insulin like growth factor, estradiol powder and glycerol
Stir, the most slowly add in gel-type vehicle, stir evenly and i.e. obtain dental pulp regeneration paste.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610861935.8A CN106267166A (en) | 2016-09-29 | 2016-09-29 | A kind of dental pulp regeneration paste and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610861935.8A CN106267166A (en) | 2016-09-29 | 2016-09-29 | A kind of dental pulp regeneration paste and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106267166A true CN106267166A (en) | 2017-01-04 |
Family
ID=57715596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610861935.8A Pending CN106267166A (en) | 2016-09-29 | 2016-09-29 | A kind of dental pulp regeneration paste and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106267166A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108379087A (en) * | 2018-03-30 | 2018-08-10 | 徐崇明 | A kind of filling paste and preparation method thereof for dental pulp expectant treatment |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813935A (en) * | 2012-03-29 | 2012-12-12 | 余东方 | Application of non-woven fabric in preparing drug for treating oral diseases and preparation |
| CN104547856A (en) * | 2014-12-18 | 2015-04-29 | 苏敏华 | Traditional Chinese medicine composition for treating periodontitis, gel preparation and preparation method thereof |
| CN105641337A (en) * | 2014-11-10 | 2016-06-08 | 于明梅 | Compound Yushang ointment |
-
2016
- 2016-09-29 CN CN201610861935.8A patent/CN106267166A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813935A (en) * | 2012-03-29 | 2012-12-12 | 余东方 | Application of non-woven fabric in preparing drug for treating oral diseases and preparation |
| CN105641337A (en) * | 2014-11-10 | 2016-06-08 | 于明梅 | Compound Yushang ointment |
| CN104547856A (en) * | 2014-12-18 | 2015-04-29 | 苏敏华 | Traditional Chinese medicine composition for treating periodontitis, gel preparation and preparation method thereof |
Non-Patent Citations (8)
| Title |
|---|
| 尚佳健 等: "壳聚糖在口腔医学中的应用研究", 《北京口腔医学》 * |
| 徐皑 等: "胰岛素样生长因子-Ⅰ和转化生长因子-β1对人牙髓干细胞增殖和分化影响的研究"", 《现代预防医学》 * |
| 方亮 等: "《药剂学》", 31 March 2016, 中国医药科技出版社 * |
| 李宝国 等: "云南白药合剂盖髓效果临床观察", 《时珍国医药学》 * |
| 李文静 等: "17β-雌二醇对人牙髓细胞增殖影响的体外研究", 《河北医药》 * |
| 林红 等: "《口腔材料学》", 31 December 2013, 北京大学医学出版社 * |
| 罗明生 等: "《药用辅料大全》", 31 January 2006, 四川科学技术出版社 * |
| 谭红 等: "新型抗菌糊剂对感染根管内细菌杀灭作用的体内研究", 《实用口腔医学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108379087A (en) * | 2018-03-30 | 2018-08-10 | 徐崇明 | A kind of filling paste and preparation method thereof for dental pulp expectant treatment |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Witherspoon et al. | Retrospective analysis of open apex teeth obturated with mineral trioxide aggregate | |
| Asgary et al. | Periradicular regeneration after endodontic surgery with calcium-enriched mixture cement in dogs | |
| Trope | Treatment of immature teeth with non‐vital pulps and apical periodontitis | |
| Nosrat et al. | Calcium-enriched mixture cement as artificial apical barrier: A case series | |
| Thibodeau | Case report: pulp revascularization of a necrotic, infected, immature, permanent tooth | |
| Kim et al. | Pulpal reaction to caries and dental procedures | |
| Annamalai et al. | Efficacy of mineral trioxide aggregate as an apical plug in non-vital young permanent teeth: preliminary results | |
| CN103961371B (en) | A kind of dental treatment thing with multi-efficiency and compositions thereof | |
| CN106309483A (en) | Inflammation-diminishing paste for dental pulp, and preparation method of inflammation-diminishing paste | |
| RU2624131C1 (en) | Method of treatment of chronic apical periodontitis | |
| Khetarpal et al. | Revascularization of immature permanent tooth with periapical lesion using a new biomaterial-A case report | |
| CN106267166A (en) | A kind of dental pulp regeneration paste and preparation method thereof | |
| CN109731145A (en) | A kind of root canal disinfection core and preparation method thereof convenient for clinical manipulation | |
| RU2452461C1 (en) | Combined medicated paste for conservative treatment of acute local pulpitis | |
| Farsi et al. | Revascularization of dental pulp in human necrotic permanent teeth with immature apex: Three case reports | |
| RU2548505C1 (en) | Method of treating chronic apical periodontitis | |
| CN105853238A (en) | Dental composition for detecting and removing dentin caries tissue and preventing carious lesion | |
| Pathak et al. | PRF as a pulpotomy medicament in a permanent molar with pulpitis: a case report | |
| RU2370238C1 (en) | Method of apical periodontitis treatment | |
| RU2521204C1 (en) | Method of treating apical periodontitis | |
| Muhamad et al. | Management of open apex in permanent teeth with biodentine | |
| RU2539422C1 (en) | Method of treating dental caries | |
| CN114028239B (en) | Root canal disinfection paste and preparation method thereof | |
| Jain et al. | Single Visit Apexification Technique for Inducing Root-End Barrier Formation in Apical Closures: Report of Two Cases | |
| Zmener et al. | Direct Pulp Capping in Osteoporotic Rats Treated with Zoledronic Acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |